drugset

drugset / Trial / NCT07199777

A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients

NCT07199777 ↗

Phase 2 Not yet recruiting 60 enrolled SciNeuro

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.

Timeline

Start: 2025-11
Primary completion: 2026-11
Completion: 2027-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SNP318	Small molecule	—	Oral

Indications